AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 291 min read$TEVA

Teva Pharma Secures FDA Nod For DEGEVMA, A Biosimilar To Xgeva

Teva Pharmaceutical (TEVA) received FDA approval for DEGEVMA, a biosimilar to Xgeva. The approval is based on data showing comparable efficacy, safety, and immunogenicity. DEGEVMA is indicated for bone complications in cancer patients and other conditions. Teva plans to launch DEGEVMA and PONLIMSI in the U.S. soon. TEVA stock closed at $38.88, up 0.31% in after-hours trading.

Original reporting
rttnews.com
Published Sep 29, 2026, 6:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 7:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefRegulation
Primary signal
$TEVA
Bullish
high confidence
Mentioned
$TEVA
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$TEVABullishMed
01

Why it matters

Regulatory clearance is a catalyst for revenue growth and may improve investor sentiment toward Teva.

02

Market read

First-time FDA approval for DEGEVMA creates a new trading catalyst for TEVA.

03

What to watch

Reimbursement negotiations and market uptake rates could be slower than anticipated.

Relevance 8/10Novelty 8/10Timing: after-hours today

Background

Teva recently launched PONLIMSI, another denosumab biosimilar, and now adds DEGEVMA to complete its portfolio.

Company-level read

Ticker impact

$TEVABullishHigh confidence
Context

FDA approval of DEGEVMA, a biosimilar to Xgeva, is a new regulatory event for Teva Pharmaceutical Industries.

Expected impact

likely modest upside as investors price in the new product launch

Evidence & confidence

First report of the approval; biosimilar adds revenue potential and aligns with market expectations for growth.

Market effects

Sector

strengthens the oncology biosimilar segment and may pressure peers like Amgen and Amgen's biosimilar pipeline.

Regional

U.S. market sees added competition in denosumab space; European markets already have approval.

Global

adds to global biosimilar competition, potentially influencing pricing dynamics worldwide.

Counterpoint

What could challenge this read

If pricing is aggressive, the approval may compress margins and limit upside.

Key entities

  • company
    Teva Pharmaceutical Industries Ltd.

    US-listed pharmaceutical company receiving FDA approval.

  • regulator
    FDA

    U.S. agency granting the biosimilar approval.

Read at source← All news

Also covered by

6 outlets

Related articles

SEP 30
$TEVALow

Teva Pharmaceutical Names Serge Rogasik CEO of TAPI Division, Ti

Teva Pharmaceutical (TEVA) appointed Serge Rogasik as CEO of its Technology & API Services division. The company's stock is trading at $39.60, 137.8% above its GF Value™ of $16.65, indicating significant overvaluation. TEVA has a GF Score™ of 60, with strengths in profitability and momentum but weaknesses in financial strength, growth, and valuation. Insiders have sold $14.6 million in shares over the past year with no insider buying.

gurufocus.com2 min
SEP 30
$TEVAMedAI 8/10

Denosumab Biosimilar Approved For Existing Oncology Indications

The FDA approved Teva's Degevma (denosumab-adet) as a biosimilar to Xgeva (denosumab) for oncology-related bone disease indications. This is Teva's second biosimilar approval in 2026, following Ponlimsi (denosumab-adet) for osteoporosis. The approval covers prevention of skeletal-related events, treatment of giant cell tumor of bone, and hypercalcemia of malignancy.

targetedonc.com2 min
SEP 30
$TEVAHighAI 9/10

Teva's Denosumab-Adet (Degevma) Approved as Xgeva Biosimilar

Teva Pharmaceutical Industries announced FDA approval of denosumab-adet (Degevma), a biosimilar to Amgen's Xgeva, for multiple indications including bone metastases and giant cell tumor. Approval was based on comparable efficacy and safety data. Teva anticipates U.S. launch in coming months, marking its second FDA-approved biosimilar in 2026.

biopharminternational.com2 min
SEP 30
$TEVAMedAI 9/10

FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy

The FDA approved Teva Pharmaceuticals' denosumab-adet (Degevma) as a biosimilar to denosumab (Xgeva) for multiple indications, including skeletal-related events in cancer patients. This follows the March 2026 approval of denosumab-adet (Ponlimsi) as a biosimilar to denosumab (Prolia). Teva expects to launch both biosimilars in the U.S. soon, according to the company.

onclive.com2 min
SEP 29
$TEVAHighAI 9/10

FDA nod for Teva’s Degevma biosimilar

Teva Pharmaceutical Industries (TEVA) received FDA approval for Degevma, a biosimilar to Amgen's Xgeva (denosumab). Degevma is indicated for preventing bone complications in advanced cancer, treating giant cell tumors, and managing hypercalcemia of malignancy. This approval expands Teva's oncology portfolio.

thepharmaletter.com2 min